NVUS Novus Therapeutics Inc.

4.45
-0.3  -6%
Previous Close 4.75
Open 4.78
Price To Book 2.29
Market Cap 41928536
Shares 9,422,143
Volume 26,583
Short Ratio
Av. Daily Volume 38,578

NewsSee all news

  1. Novus Therapeutics to Participate in the 8th Annual SVB Leerink Global Healthcare Conference
  2. Novus Therapeutics Doses First Patients in Phase 2a Trial of OP0201
  3. Company Profile for Novus Therapeutics, Inc.
  4. Novus Therapeutics Doses First Subjects in Phase 1 Pharmacodynamics Study of OP0201
  5. Novus Therapeutics Advances OP0201 Development Program Across Several Clinical Trials

SEC filingsSee all SEC filings

  1. 8-K - Current report 19515283
  2. 8-K - Current report 181175195
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181174272
  4. RW - Registration Withdrawal Request 181058955
  5. S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933 181052779

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial discontinued July 2016 due to poor data
Galeterone - ARMOR3-SV
Cancer - castration-resistant prostate cancer (CRPC)
Announced in August 2016 that Phase 2 trial enrollment has been discontinued.
Galeterone - ARMOR2
Xtandi (enzalutamide) refractory metastatic castration-resistant prostate cancer (mCRPC)
Phase 1 data due 2Q 2019.
OP0201
Healthy volunteers
Phase 1 trial to be initiated 4Q 2018 with data due 1H 2019.
OP-02
Healthy volunteers
Phase 1 data due 1Q 2019.
OP0201
Acute Otitis Media - adults
Phase 2a dosing has commenced - noted February 19, 2019 data due 2H 2019.
OP0201
Acute Otitis Media - children
Phase 1 commencement of dosing announced February 11, 2019.
OP0201
Healthy volunteers

Latest News

  1. Novus Therapeutics to Participate in the 8th Annual SVB Leerink Global Healthcare Conference
  2. Novus Therapeutics Doses First Patients in Phase 2a Trial of OP0201
  3. Company Profile for Novus Therapeutics, Inc.
  4. Novus Therapeutics Doses First Subjects in Phase 1 Pharmacodynamics Study of OP0201
  5. Novus Therapeutics Advances OP0201 Development Program Across Several Clinical Trials
  6. Novus Therapeutics Doses First Patient with Acute Otitis Media in Phase 1 Study of OP0201
  7. Can We See Significant Institutional Ownership On The Novus Therapeutics, Inc. (NASDAQ:NVUS) Share Register?
  8. Novus Therapeutics Announces Formation of Scientific Advisory Board
  9. Novus Therapeutics Doses First Subjects in Phase 1 Study of OP0201
  10. Novus Therapeutics to Present at the 2018 Piper Jaffray Healthcare Conference
  11. Novus Therapeutics Reports Third Quarter 2018 Financial Results
  12. Novus Therapeutics to Present at the Ladenburg Thalmann 2018 Healthcare Conference
  13. Novus Therapeutics to Postpone Offering of Common Stock
  14. Novus Therapeutics Announces Proposed Public Offering of Common Stock
  15. Novus Therapeutics Reports Second Quarter 2018 Financial Results
  16. Novus Therapeutics Receives FDA Guidance at Type C Meeting for OP-02 in the Treatment and Prevention of Otitis Media
  17. Novus Therapeutics Reports First Quarter 2018 Financial Results
  18. Novus Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update

SEC Filings

  1. 8-K - Current report 19515283
  2. 8-K - Current report 181175195
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181174272
  4. RW - Registration Withdrawal Request 181058955
  5. S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933 181052779
  6. 8-K - Current report 18996385
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 18995758
  8. S-1 - General form for registration of securities under the Securities Act of 1933 18982301
  9. EFFECT - Notice of Effectiveness 18982849
  10. UPLOAD [Cover] - SEC-generated letter